Physician profile
Robert Ritch
NPI 1821078874
$10,342.46
in general payments reported to CMS, 2019-2025
14 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,582 · 2020: $392 · 2021: $78.12 · 2023: $156 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $290.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nidek Co., Ltd. | $9,060.00 | 2019 | |
| Sight Sciences, INC. | $308.72 | 2019 | |
| Rxsight INC | $234.37 | 2021-2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Johnson & Johnson Surgical Vision, INC. | $134.31 | 2025 | Tecnis Iol |
| Allergan, INC. | $131.24 | 2019 | |
| Sun Pharmaceutical Industries INC. | $125.00 | 2020 | |
| Eyepoint US, INC. | $107.14 | 2020 | |
| Glaukos Corporation | $96.15 | 2020 | |
| Novartis Pharmaceuticals Corporation | $50.00 | 2019 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Aerie Pharmaceuticals, INC. | $31.70 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $25.03 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$15,822.37 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ritch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.